Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Contributed by: Business Wire

Logo

Tags

Research

Genetics

Clinical Trials

Cardiology

Biotechnology

Health

Pharmaceutical

Other Science

Science

ADS capital financing mRNAi siRNA polycythemia medicine hematology cardiology

More Like This

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results